Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Identify Breast Cancer (IDBC) (IDBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04495244
Recruitment Status : Recruiting
First Posted : July 31, 2020
Last Update Posted : July 31, 2020
Sponsor:
Information provided by (Responsible Party):
Syantra Inc.

Brief Summary:

Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.

The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.


Condition or disease Intervention/treatment
Breast Cancer Female Diagnostic Test: Syantra DX Breast Cancer

Detailed Description:

The current project is aimed at validating Syantra DX Breast Cancer in a UK population. Results of the UK study will be combined with those from additional sites, including those in Canada, with additional samples expected from the United States and South Korea. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed, and is described below.

The study seeks to evaluate performance of Syantra DX Breast Cancer in prospective samples and to optimize test methodology and biomarkers. Key to performance of the study is recruitment of women who have received an abnormal mammography report, and have been classified under the UK Royal College of Radiologists Breast Group (RCRBG) scoring system in categories 3 - 5. This will support the ability to employ the test for breast cancer detection in a screening/call-back environment. To complete the study cohort, additional women will be recruited from the population who have normal or benign mammography results (RCRBG category 1 and 2), and/or a recent normal physical breast exam, with no history of breast cancer. Blood samples will be acquired from all women following completion of an informed consent procedure.

For those with an abnormal mammogram, blood will be drawn before a biopsy is performed. All sample information will be de-identified, and the samples will be processed and analysed according to Syantra DX Breast Cancer standard operating procedures. These procedures include extracting sample RNA and aliquoting for storage in a manner that maintains sample anonymity. All processing and analysis will be conducted in a blind environment without knowing the associated RCRBG or pathology outcomes for any samples. Only after testing is complete will sample classifications be revealed. Syantra DX Breast Cancer results will then be compared to RCRBG, biopsy and pathology data to determine concordance, and statistics will be calculated. If or when biomarker panel or test methodology is modified during the performance of the study, samples will be reanalysed with updated test parameters. This reanalysis will make use of a de-identified aliquot of sample RNA to ensure that testing is maintained in a blind environment.

There is an optional part of the study procedure that is included as 'additional research'. A specific question seeking approval for the additional research is included on the study consent form. For individuals who agree to participate in the additional research, material extracted from their blood sample will be stored for additional investigations.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)
Actual Study Start Date : January 24, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort Intervention/treatment
Investigational Population

Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.

Inclusion criteria

  • Women with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
  • Individuals with an abnormal or suspicious screening mammogram recalled for further evaluation.
  • Suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
  • Willing to give written Informed Consent and provide whole blood samples
  • Age 30-75 years

Exclusion criteria

  • Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
  • Inoperable (T4 category) or inflammatory breast cancer
  • Previous history of cancer previously at any site
  • Previous history of breast cancer
  • Concomitant or other concurrent anti-cancer therapy
  • Male
  • No histopathological diagnosis
Diagnostic Test: Syantra DX Breast Cancer
Blood test for detecting the presence of breast cancer.

Borderline (Atypica and LCIS) Population

Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria

  • Abnormal screening mammogram with suspected benign breast disease or proliferative changes
  • Willing to give Written Informed Consent and provide whole blood samples
  • Aged 30-75 years

Exclusion criteria

  • Existing cancer diagnosis
  • Male
  • Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
  • Previous history of any cancer
  • Previous history of breast cancer
  • Concomitant or other concurrent anti-cancer therapy
Diagnostic Test: Syantra DX Breast Cancer
Blood test for detecting the presence of breast cancer.

Control Population

Healthy Controls Inclusion criteria

  • Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
  • Willing to give Written Informed Consent and provide whole blood samples
  • Aged 30-75 years

Exclusion criteria

  • Cancer diagnosis
  • Male
  • Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
  • Previous history of any cancer
  • Concomitant or other concurrent anti-cancer therapy
Diagnostic Test: Syantra DX Breast Cancer
Blood test for detecting the presence of breast cancer.




Primary Outcome Measures :
  1. Performance of the Syantra DX Breast Cancer test as assessed by sensitivity and specificity [ Time Frame: through completion of the study, approximately eighteen months ]
    The number of participants that test positive or negative for breast cancer with the Syantra DX Breast Cancer test and their breast cancer status as assessed by mammography or pathology.


Secondary Outcome Measures :
  1. Modulate test methodology to account for differences between retrospective and prospective samples [ Time Frame: through completion of the study, approximately eighteen months ]
    Determine the sensitivity and specificity of the assay with biomarker panel modifications.

  2. Performance of the Syantra DX Breast Cancer test in prediction of molecular subtype of breast cancer as assessed by pathology [ Time Frame: through completion of the study, approximately eighteen months ]
    Correlate the performance of the test to molecular characterizations of identified cancers as assessed by pathology of tissue from biopsy or resection.


Biospecimen Retention:   Samples Without DNA
Whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Self-identified
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Populations will be selected from women visiting the Nightingale Centre at Wythenshaw Hospital for breast cancer imaging.
Criteria

Inclusion criteria

  • Aged 30-75 years
  • Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
  • Women with suspected Invasive Breast Cancer
  • Individuals with an abnormal or suspicious mammogram
  • Abnormal screening mammogram with suspected benign breast disease or proliferative changes

Exclusion criteria

  • Cancer diagnosis
  • Male
  • Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
  • Previous history of any cancer
  • Concomitant or other concurrent anti-cancer therapy
  • Inoperable or inflammatory breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04495244


Contacts
Layout table for location contacts
Contact: Hayley Brooks 0161 291 4045 Hayley.brooks@mft.nhs.uk
Contact: Linda Bailey 0161 291 4492 linda.bailey3@mft.nhs.uk

Locations
Layout table for location information
United Kingdom
Wythenshawe Hospital, Southmoor Road Recruiting
Manchester, United Kingdom, M23 9LT
Contact: Hayley Brooks         
Principal Investigator: Nigel Bundred, MD         
Sponsors and Collaborators
Syantra Inc.
Investigators
Layout table for investigator information
Principal Investigator: Nigel Bundred, MD Manchester University NHS Foundation Trust
Study Director: Cliona Kirwin, MD Manchester University NHS Foundation Trust
Layout table for additonal information
Responsible Party: Syantra Inc.
ClinicalTrials.gov Identifier: NCT04495244    
Other Study ID Numbers: 241391
First Posted: July 31, 2020    Key Record Dates
Last Update Posted: July 31, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Syantra Inc.:
Detection, blood test, clinical assay
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases